Current status of ramucirumab in gastroesophageal adenocarcinoma.

Current status of ramucirumab in gastroesophageal adenocarcinoma.

Future Oncol. 2017 Apr 24;:

Authors: Elimova E, Lin Q, Song S, Ajani JA

Abstract
Outcomes of patients with advanced gastric or gastroesophageal junction adenocarcinoma (GEAC) remain poor despite recent advances. The standard of care in the management of this disease had not changed much over the past decade. In the first line, a platinum containing doublet/triplet is used, while in <20% of patients with human epithelial growth factor receptor type 2 overexpressing GEACs, trasuzumab can provide a modest advantage. Until recently, no standard second-line regimens existed; however, the results of the REGARD and RAINBOW trials led to the approval of ramucirumab in the second-line setting. From these trials it is clear that paclitaxel and ramucirumab should be used if possible. The placement of ramucirumab may become less clear as the data from immune oncology trials in GEAC emerge.

PMID: 28436242 [PubMed - as supplied by publisher]

http://ift.tt/2pZTtaL